求助书籍

wenwen629

Dübel, Stefan (ed.)
/ W: I0 o. d. i- A  aHandbook of Therapeutic Antibodies
1 J& H# |; P  vTechnologies, Emerging Developments and Approved Therapeutics
' c3 H! x: \, y7 Y! l$ h/ s' T5 c
1. Edition - July 2010; d4 |) y! g2 T
199.- Euro
) x: \3 c) z/ ?3 O# ^2010. XLVI, 1204 Pages, Softcover
* x1 X$ I# Y0 |  p2 z8 [" v200 Fig. (100 Colored Fig.)
, ]  n, Y$ ]2 O$ q- x- Handbook/Reference Book -8 M+ i+ S" d$ x
ISBN-10: 3-527-32902-1
5 V4 y0 V  R& }8 d) ^& a: }有目录也可，求书！

hdc2001

我也想要。

hdc2001

Section I: Technologies+ A4 T8 f0 W. t5 g; E$ X4 M
Foreword
$ B. ~' I- E' vA Greeting from the Editor8 w. U& V. y5 J
PART 0: INTRODUCTION* g3 R% i8 [- U; F) A
Therapeutic Antibodies - From Past to Future : o3 |0 A' M" B9 }- o6 |' P
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE5 Q, m6 ]3 I+ W
Selection strategies I: Monoclonal Antibodies1 R6 [( `9 Z- g+ U! t' S
Selection strategies II: Antibody Phage Display
* e1 [! E. D/ E5 {, E& vSelection strategies III: Transgenic Mice
! o9 w9 Q/ T7 j% @Bioinformatic Tools for Antibody Engineering4 G$ k; w8 R  H
Molecular Engineering I: Humanization
, U2 r) ^/ L) F) ^! V& Y% k4 xMolecular Engineering II: Affinity Maturation
; U5 A) ~. y- y) ]9 y0 wMolecular Engineering III: Fc Engineering
# x, ~+ S* h) Y1 ~5 c. h  w/ mPART II: THE WAY INTO THE CLINIC+ X- j' R0 l8 j2 s; m
Production and Downstream Processing " k* |, |. z; b( @' y& }5 n3 m- M: E
Pharmaceutical Formulation and Clinical Application
4 o8 I8 O. e8 F8 k. q7 _Immunogenicity of Antibody Therapeutics 5 T  C; g- L2 y
Regulatory Considerations
9 ^& H! W! G# U$ h$ J0 W- aIntellectual Property Issues
4 i; n/ J  ]  x3 L5 L8 E
6 ]! t! e# e7 v% A8 sSection II: Emerging Developments2 w0 _! d2 f& E, q
PART III: BEYOND IGG: MODIFIED ANTIBODIES
3 G4 V# F; d, w7 s5 qImmunoscintigraphy and Radioimmunotherapy ( G* Y3 Y* }# u9 `; y$ f; E
Bispecific Antibodies
* P  i2 Z# h: v- k% k3 h# ^1 a; cImmunotoxins /
& k, r9 a% t4 w1 N9 G. Y5 cTargeted RNases 0 i! x+ a0 Y- p$ H. n! r
PART IV: EMERGING CONCEPTS2 Z1 ^) ~4 L/ @1 Q( Q  D$ T
Automation of Selection and Engineering
( a, W0 X+ Z. O% m* s8 [' LEmerging Technologies for Antibody Selection - @( K- K$ v4 `- x9 L8 h
Emerging Alternative Production Systems
- l0 P* E' L5 Y8 iNon-Antibody Scaffolds ' w4 m: H% y* _( P. I+ M. V* Q* x
Emerging Therapeutic Concepts I: ADEPT# a* X9 Q% J5 X# |) {! Z$ Y
Emerging Therapeutic Concepts II: Nanotechnology
' r; F# e/ f7 g+ {/ L$ g: t7 zEmerging Therapeutic Concepts III:Cell-bound antibodies1 y6 p( k3 {6 w- t/ w; n
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies8 P# k7 D* |  _6 D4 u2 G+ j4 f
PART V: ONGOING CLINICAL STUDIES:: |5 t$ @8 f% U4 O; X, n
Antibodies in Phase I/II/III: Cancer Therapy - ^! _  w: `9 T) c* T0 v
Antibodies in Phase I/II/III: Targeting TNF& E* ~6 n7 ~) k0 n* Z0 P: I% n

; V5 [$ X3 ], g% T  KSection III: APPROVED THERAPEUTICS
  W) T" p: v# Y& s& h8 V% q4 yAdalimumab (Humira)5 I1 C$ P6 e2 K; A9 k
Alemtuzumab (Mabcampath)
* j# x9 O. X5 ^# n1 RBevacizumab (Avastin)
9 |1 s. Z0 Q) z! e7 JCetuximab (Erbitux)
8 _8 e: c) a$ H0 T4 z, eEfalizumab (Raptiva)5 z& o# [: B; r- i4 Z
Fanolesomab/Technetium99m (Neutrospec)
' D! G' j2 f0 u7 t4 }Gemtuzumab Ozogamicin (Mylotarg)" c9 c- M% T3 k5 d- O" X" S2 j
Infliximab (Remicade)
/ T. x. L0 K- ?) B7 n( h5 yMuromonab (Orthoclone)
9 y. J+ s' t- y1 o6 i0 KNatalizumab (Tysabri)) P6 j8 O# l2 B7 j, K$ p# |
Omalizumab (Xolair)+ {- z% z* Z$ D" O
Palivizumab (Synagis)
+ t3 E, {0 O% D9 }& NRituximab (Rituxan), N8 O7 L2 m- i$ O6 {
Trastuzumab (Herceptin)( y: Q$ o' V) i! y: ]9 ^" W
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
& O1 e& v9 Q& a# Y# MYttrium-90 Ibritumomab Tiuxetan (Zevalin)8 x2 j1 F( i. v0 \/ L% Q

wenwen629

回复 hdc2001 的帖子$ u5 d& |3 z1 B# d7 y2 U4 m# k: ~
. a/ T! Q8 b) i6 Q- B& x
谢谢。